Tight Junctions, Intestinal Permeability, and Autoimmunity

Autoimmune diseases are characterized by tissue damage and loss of function due to an immune response that is directed against specific organs. This review is focused on celiac disease (CD), an autoimmune enteropathy, and type 1 diabetes (T1D), a hyperglycosaemia caused by a destructive autoimmune process targeting the insulin‐producing pancreatic islet cells. Even if environmental factors and genetic susceptibility are clearly involved in the pathogenesis of autoimmunity, for most autoimmune disorders there is no or little knowledge about the causing agent or genetic makeup underlying the disease. In this respect, CD represents a unique autoimmune disorder because a close genetic association with HLA‐DQ2 or HLA‐DQ8 haplotypes and, more importantly, the environmental trigger (the gliadin fraction of gluten‐containing grains wheat, barley, and rye) are known. Conversely, the trigger for autoimmune destruction of pancreatic ß cells in T1D is unclear. Interestingly, recent data suggest that gliadin is also involved in the pathogenesis of T1D. There is growing evidence that increased intestinal permeability plays a pathogenic role in various autoimmune diseases including CD and T1D. Therefore, we hypothesize that besides genetic and environmental factors, loss of intestinal barrier function is necessary to develop autoimmunity. In this review, each of these components will be briefly reviewed.

[1]  Sefik Alkan,et al.  Gliadin induces an increase in intestinal permeability and zonulin release by binding to the chemokine receptor CXCR3. , 2008, Gastroenterology.

[2]  D. Elias,et al.  Neonatal oral administration of DiaPep277, combined with hydrolysed casein diet, protects against Type 1 diabetes in BB-DP rats. An experimental study , 2004, Diabetologia.

[3]  A. Fasano,et al.  Intestinal zonulin: open sesame! , 2001, Gut.

[4]  M. Rewers,et al.  Timing of initial cereal exposure in infancy and risk of islet autoimmunity. , 2003, JAMA.

[5]  B. L.,et al.  Prevalence of Coeliac Disease: Unexplained Age-related Variation in the Same Population , 2003 .

[6]  P. Brandtzaeg.  Overview of the mucosal immune system. , 1989, Current topics in microbiology and immunology.

[7]  Ronald H. Zielke,et al.  Role of the intestinal tight junction modulator zonulin in the pathogenesis of type I diabetes in BB diabetic-prone rats. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[8]  L. Sollid.  Breast milk against coeliac disease , 2002, Gut.

[9]  F. Koning,et al.  The HLA-DQ2 gene dose effect in celiac disease is directly related to the magnitude and breadth of gluten-specific T cell responses , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[10]  L. Greco,et al.  Concordance, disease progression, and heritability of coeliac disease in Italian twins , 2005, Gut.

[11]  J. Bassaganya-Riera,et al.  Putting the pieces of the puzzle together - a series of hypotheses on the etiology and pathogenesis of type 1 diabetes. , 2007, Medical hypotheses.

[12]  L. Sollid,et al.  HLA in coeliac disease: unravelling the complex genetics of a complex disorder. , 2003, Tissue antigens.

[13]  A. Bocca,et al.  Prevalence of coeliac disease: unexplained age-related variation in the same population. , 2003, Scandinavian journal of gastroenterology.

[14]  A. Fasano,et al.  Zonulin, a newly discovered modulator of intestinal permeability, and its expression in coeliac disease , 2000, The Lancet.

[15]  J. Murray,et al.  Prevalence of celiac disease in at-risk and not-at-risk groups in the United States: a large multicenter study. , 2003, Archives of internal medicine.

[16]  H. Kolb,et al.  Oral exposure to diabetes-promoting food or immunomodulators in neonates alters gut cytokines and diabetes. , 2002, Diabetes.

[17]  A. Fasano.  Pathological and Therapeutical Implications of Macromolecule Passage through the Tight Junction , 2001 .

[18]  M. De Vos,et al.  Major histocompatibility complex class II antigen (HLA-DR) expression by ileal epithelial cells in patients with seronegative spondylarthropathy. , 1990, Gut.

[19]  E. Thorsby,et al.  Gliadin-specific, HLA-DQ(alpha 1*0501,beta 1*0201) restricted T cells isolated from the small intestinal mucosa of celiac disease patients , 1993, The Journal of experimental medicine.

[20]  J. Strubbe,et al.  The diabetes prone BB rat model of IDDM shows duration of breastfeeding to influence Type 1 diabetes development later in life , 2003, Diabetologia.

[21]  A. Fasano,et al.  Zonula occludens toxin structurefunction analysis. Identification of the fragment biologically active on tight junctions and of the zonulin receptor binding domain , 2000 .

[22]  J. Ilonen,et al.  Immunologic activity in the small intestinal mucosa of pediatric patients with type 1 diabetes. , 2003, Diabetes.

[23]  A. Levi,et al.  Effect of non-steroidal anti-inflammatory drugs and prostaglandins on the permeability of the human small intestine. , 1986, Gut.

[24]  O. Simell,et al.  Endothelial Cell-Binding Properties of Lymphocytes Infiltrated Into Human Diabetic Pancreas: Implications for Pathogenesis of IDDM , 1993, Diabetes.

[25]  J. Madara,et al.  Partitioning of paracellular conductance along the ileal crypt-villus axis: A hypothesis based on structural analysis with detailed consideration of tight junction structure-function relationships , 2005, The Journal of Membrane Biology.

[26]  C. Fiorentini,et al.  Zonula occludens toxin modulates tight junctions through protein kinase C-dependent actin reorganization, in vitro. , 1995, The Journal of clinical investigation.

[27]  S. Salminen,et al.  Aberrant composition of gut microbiota of allergic infants: a target of bifidobacterial therapy at weaning? , 2002, Gut.

[28]  Giuseppe Iacono,et al.  Gliadin, zonulin and gut permeability: Effects on celiac and non-celiac intestinal mucosa and intestinal cell lines , 2006, Scandinavian journal of gastroenterology.

[29]  Å. Lernmark,et al.  Prediction of silent celiac disease at diagnosis of childhood type 1 diabetes by tissue transglutaminase autoantibodies and HLA , 2001, Pediatric diabetes.

[30]  D. E. Lefebvre,et al.  Dietary proteins as environmental modifiers of type 1 diabetes mellitus. , 2006, Annual review of nutrition.

[31]  E. Bonifacio,et al.  Early infant feeding and risk of developing type 1 diabetes-associated autoantibodies. , 2003, JAMA.

[32]  J. Kaper,et al.  Cloning of a gene (zot) encoding a new toxin produced by Vibrio cholerae , 1992, Infection and immunity.

[33]  J. Ilonen,et al.  Jejuna of patients with insulin‐dependent diabetes mellitus (IDDM) show signs of immune activation , 1999, Clinical and experimental immunology.

[34]  S. Virgiliis,et al.  Early effects of gliadin on enterocyte intracellular signalling involved in intestinal barrier function , 2003, Gut.

[35]  A. Fasano,et al.  The enterotoxic effect of zonula occludens toxin on rabbit small intestine involves the paracellular pathway. , 1997, Gastroenterology.

[36]  D. E. Lefebvre,et al.  Wheat protein-induced proinflammatory T helper 1 bias in mesenteric lymph nodes of young diabetes-prone rats , 2005, Diabetologia.

[37]  K. Buschard,et al.  Gluten‐free but also gluten‐enriched (gluten+) diet prevent diabetes in NOD mice; the gluten enigma in type 1 diabetes , 2008, Diabetes/metabolism research and reviews.

[38]  H. Kolb,et al.  Potential Mechanisms by Which Certain Foods Promote or Inhibit the Development of Spontaneous Diabetes in BB Rats: Dose, Timing, Early Effect on Islet Area, and Switch in Infiltrate From Th1 to Th2 Cells , 1997, Diabetes.

[39]  H. Harmsen,et al.  Antibiotic treatment partially protects against type 1 diabetes in the Bio-Breeding diabetes-prone rat. Is the gut flora involved in the development of type 1 diabetes? , 2006, Diabetologia.

[40]  A. Fasano,et al.  Purification and preliminary characterization of the zonula occludens toxin receptor from human (CaCo2) and murine (IEC6) intestinal cell lines. , 2001, FEMS microbiology letters.

[41]  P. Krajči,et al.  Immunobiology and immunopathology of human gut mucosa: humoral immunity and intraepithelial lymphocytes. , 1989, Gastroenterology.

[42]  P. Kero,et al.  Importance of intestinal colonisation in the maturation of humoral immunity in early infancy: a prospective follow up study of healthy infants aged 0–6 months , 2000, Archives of disease in childhood. Fetal and neonatal edition.

[43]  L. Greco,et al.  In vitro-deranged intestinal immune response to gliadin in type 1 diabetes. , 2004, Diabetes.

[44]  C. Wijmenga,et al.  Associations with tight junction genes PARD3 and MAGI2 in Dutch patients point to a common barrier defect for coeliac disease and ulcerative colitisAn unusual case of ascites , 2007, Gut.

[45]  M. A. Saper,et al.  Structure of the human class I histocompatibility antigen, HLA-A2 , 1987, Nature.

[46]  G. Coppa,et al.  Host-dependent zonulin secretion causes the impairment of the small intestine barrier function after bacterial exposure. , 2002, Gastroenterology.

[47]  J. Strubbe,et al.  Short-term dietary adjustment with a hydrolyzed casein-based diet postpones diabetes development in the diabetes-prone BB rat. , 2003, Metabolism: clinical and experimental.

[48]  A. Fasano,et al.  Human zonulin, a potential modulator of intestinal tight junctions. , 2000, Journal of cell science.

[49]  Dario Iafusco,et al.  Zonulin Upregulation Is Associated With Increased Gut Permeability in Subjects With Type 1 Diabetes and Their Relatives , 2006, Diabetes.

[50]  J. Hardin,et al.  Increased gastrointestinal permeability is an early lesion in the spontaneously diabetic BB rat. , 1999, American journal of physiology. Gastrointestinal and liver physiology.

[51]  A. Mowat,et al.  Anatomical basis of tolerance and immunity to intestinal antigens , 2003, Nature Reviews Immunology.

[52]  M. A. Kelly,et al.  Molecular aspects of type 1 diabetes , 2003, Molecular pathology : MP.

[53]  R Balfour Sartor,et al.  Therapeutic manipulation of the enteric microflora in inflammatory bowel diseases: antibiotics, probiotics, and prebiotics. , 2004, Gastroenterology.

[54]  D. Wendling.  [Role of the intestine in the physiopathology of inflammatory rheumatism]. , 1992, Revue du rhumatisme et des maladies osteo-articulaires.

[55]  E. G. de la Concha,et al.  Association of MYO9B haplotype with type 1 diabetes. , 2008, Human immunology.

[56]  A. Levi,et al.  Intestinal permeability: clinical correlates. , 1986, Digestive diseases.

[57]  Cisca Wijmenga,et al.  Myosin IXB variant increases the risk of celiac disease and points toward a primary intestinal barrier defect , 2005, Nature Genetics.

[58]  J. Kaper,et al.  Vibrio cholerae produces a second enterotoxin, which affects intestinal tight junctions. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[59]  M. A. Saper,et al.  The foreign antigen binding site and T cell recognition regions of class I histocompatibility antigens , 1987, Nature.